Literature DB >> 24878428

Prognostic implications of the standardized study of resection margins in pancreatic cancers.

Luis Sabater1, María del Carmen Gómez-Mateo2, Javier López-Sebastián3, Elena Muñoz-Forner4, Francisco Morera-Ocón4, Andrés Cervantes5, Susana Roselló5, Bruno Camps-Vilata5, Antonio Ferrández2, Joaquín Ortega4.   

Abstract

INTRODUCTION: Involvement of surgical resection margins is a fundamental prognostic factor in pancreatic oncological surgery. However, there is a lack of standardized histopathology definition. The aims of this study are to investigate the real rate of R1 resections when surgical specimens are evaluated according to a standardized protocol and to study its survival implications. PATIENTS Y
METHODS: One hundred consecutive surgically resected patients with pancreatic ductal adenocarcinoma were included in the study. They were further divided in 2 groups: pre-protocol, evaluated before the introduction of the standardized protocol and post-protocol, analyzed with the standardized protocol.
RESULTS: R0 resection rate in the pre-protocol group was 78%, falling to 47% after the introduction of the standardized protocol (p=0,003). The posterior retroperitoneal margin was the most frequently involved margin. In cases with tumors located at the pancreatic head and analyzed according to the standardized protocol R1 involvement negatively affected survival. Median survival in the R0 group was 22 months versus 16 in those with the margin involved (HR: 2.044; IC 95% 1,00-4,16; P=.043).
CONCLUSIONS: Standardized evaluation of the retroperitoneal margins in pancreatic cancer increases the rate of R1 patients. In cases with pancreatic cancer located at the pancreatic head involvement of posterior retroperitoneal margin significantly decreases survival.
Copyright © 2013 AEC. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Cáncer de páncreas; Duodenopancreatectomía; Oncological resection; Pancreatic cancer; Pancreatoduodenectomy; R1 resection; Resección R1; Resección oncológica

Mesh:

Year:  2014        PMID: 24878428     DOI: 10.1016/j.ciresp.2013.07.014

Source DB:  PubMed          Journal:  Cir Esp        ISSN: 0009-739X            Impact factor:   1.653


  1 in total

1.  Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

Authors:  Susana Roselló; Claudio Pizzo; Luis Sabater; Andrés Cervantes; Marisol Huerta; Elena Muñoz; Roberto Aliaga; Almudena Vera; Clara Alfaro-Cervelló; Esther Jordá; Marina Garcés-Albir; Desamparados Roda; Dimitri Dorcaratto; Noelia Tarazona; Sergio Torondel; Jorge Guijarro; Vicente Sánchiz; Valentina Gambardella; Tania Fleitas-Kanonnikoff; Paloma Lluch; Isabel Pascual; Antonio Ferrández
Journal:  ESMO Open       Date:  2020-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.